Brokerages Set vTv Therapeutics Inc. (NASDAQ:VTVT) PT at $51.33

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been given an average rating of “Moderate Buy” by the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $51.3333.

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $47.00 target price (up previously from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. TD Cowen began coverage on vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating and a $67.00 target price on the stock. Cowen began coverage on shares of vTv Therapeutics in a research note on Monday. They issued a “buy” rating for the company. Finally, Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a research report on Saturday, December 27th.

vTv Therapeutics Trading Down 13.3%

Shares of vTv Therapeutics stock opened at $35.58 on Monday. The firm’s 50-day moving average price is $32.45 and its two-hundred day moving average price is $23.17. The stock has a market capitalization of $140.19 million, a price-to-earnings ratio of -10.72 and a beta of 0.48. vTv Therapeutics has a 1-year low of $13.20 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Institutional Inflows and Outflows

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP lifted its position in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 148,314 shares of the biotechnology company’s stock after purchasing an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned about 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.